This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2040 Remove Data Remove Safety Related Topics
Clinical Trials Epilepsy Chronic Pain Decriminalization Treatment Conditions Programs Policy Access Patients More Related Topics >
article thumbnail

MyMD Pharmaceuticals President Chris Chapman, M.D. Named Medical Honoree of the Year by the Arthritis Foundation

Cannabis Law Report

OCTOBER 26, 2021

Studies estimate that the number of people suffering from rheumatoid arthritis may rise to over 78 million by 2040. 1 Data published by Research and Markets, March 2018. The rising prevalence of rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease are driving demand for TNF inhibitors like MYMD-1. 646) 421-9523.

Pharmaceutical 52
Pharmaceutical Clinical Trials Research and Development Therapy 52
article thumbnail

Schumer, Booker, Wyden Introduce Booker, Schumer, Wyden Introduce , Cannabis Administration and Opportunity Act

Cannabis Law Report

JULY 21, 2022

You might not be so excited to learn there are 296 pages of draft legislation to be read which implies to us that the amendment conversation could still be happening when Kyle Jenner is voted president in 2040. Hopefully i’ll be dead by then. Booker, Schumer, Wyden Introduce Cannabis Administration and Opportunity Act. JULY 21, 2022.

Safety 52
Safety Legislation Clinical Trials Banking 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 24,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024